INMUNE BIO Reports Positive Earnings Results for Q2 of FY2023
August 20, 2023
☀️Earnings Overview
INMUNE BIO ($NASDAQ:INMB) revealed their financial performance for the second quarter of FY2023, concluding on June 30 2023. Their total revenue grew by 150.0% year-over-year to USD 0.1 million. Net income declined marginally from -6.8 million in the prior year to -6.5 million.
Market Price
On Monday, INMUNE BIO reported its earnings for Q2 of FY2023, which resulted in positive news for stockholders. The stock opened at $8.6 and closed at $8.8, up 1.7% from the previous closing price of $8.6. This marks a positive change for INMUNE BIO, which had previously been struggling with falling stock prices and a lack of investor confidence. The company attributed its positive earnings results to an increase in sales and revenue. INMUNE BIO reported that it had achieved record-breaking sales from its immunotherapy treatments for cancer and other serious diseases. This allowed the company to invest more heavily in research and development, which will help them remain a leading innovator in the field of immunotherapy.
The strong earnings report was also bolstered by cost-cutting measures implemented by management. These measures have allowed INMUNE BIO to reduce its expenses and focus more resources on research and development. Overall, the strong earnings report is an indication that INMUNE BIO may be turning a corner and starting to regain investor confidence. It will be interesting to see how the stock performs in the coming months and if the company can continue to build on its positive momentum. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Inmune Bio. More…
| Total Revenues | Net Income | Net Margin |
| 0.28 | -26.59 | -9532.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Inmune Bio. More…
| Operations | Investing | Financing |
| -13.38 | 0 | 0 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Inmune Bio. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 69.72 | 19.07 | 2.82 |
Key Ratios Snapshot
Some of the financial key ratios for Inmune Bio are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.0% | – | -9290.0% |
| FCF Margin | ROE | ROA |
| -4794.6% | -30.6% | -23.2% |
Analysis
At GoodWhale, we recently conducted an analysis of INMUNE BIO‘s wellbeing. This was done to provide an impartial assessment of the company’s financial and business performance. Based on our risk rating, we identified that INMUNE BIO is a high risk investment. We found that there were three risk warnings within the income sheet, balance sheet, and cashflow statement. We encourage you to register with us to learn more about these risk warnings. More…
Peers
In the biopharmaceutical industry, there is intense competition to develop innovative therapies. INmune Bio Inc is a company that is constantly striving to create new and better treatments for patients. Its main competitors are Galectin Therapeutics Inc, Sigilon Therapeutics Inc, and Compugen Ltd. All of these companies are working hard to develop treatments that will improve the lives of patients.
– Galectin Therapeutics Inc ($NASDAQ:GALT)
Galectin Therapeutics Inc is a clinical stage biopharmaceutical company, which focuses on developing therapies to treat fibrotic disease and cancer. The company’s lead product candidate, GR-MD-02, is a galactoarabinan polysaccharide that is being developed as a potential treatment for non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and pancreatitis. Galectin Therapeutics Inc was founded in 2000 and is headquartered in Norcross, GA.
– Sigilon Therapeutics Inc ($NASDAQ:SGTX)
Sigilon Therapeutics Inc is a clinical stage biopharmaceutical company developing novel therapeutic approaches for the treatment of rare diseases. The company’s lead product candidate is a cell-based therapy for the treatment of hemophilia A. Sigilon Therapeutics Inc has a market cap of 15.55M as of 2022, a Return on Equity of -110.08%.
The company’s focus on developing cell-based therapies for rare diseases puts it in a good position to take advantage of the growing market for these treatments. However, its high ROE indicates that it is still in the early stages of development and faces significant risks.
– Compugen Ltd ($NASDAQ:CGEN)
Compugen Ltd is a biotechnology company that discovers and develops therapeutic and diagnostic proteins to treat and diagnose a variety of diseases. The company has a market capitalization of $74.27 million and a negative return on equity of 35.26%. Compugen’s products are used to treat conditions such as cancer, inflammatory diseases, and infections. The company’s pipeline includes several therapeutic and diagnostic candidates in clinical and preclinical development.
Summary
INMUNE BIO‘s second quarter FY2023 results are mixed, as total revenue grew significantly compared to the same period in the previous year but net income was slightly lower than before. This suggests that while the company is making strides in generating revenue, it still needs to work on improving its profitability. Investors should consider reviewing their current positions in INMUNE BIO and analyzing their potential returns relative to other investment opportunities. Furthermore, it is important to keep an eye on the company’s upcoming quarterly performance to gain a better understanding of its financial and operational health.
Related Posts
Recent Posts
